Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

275.84 +5.40 (+2.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
53 54 Next >
Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents
Amgen Inc (NASDAQ: AMGN) has reportedly sued Novartis AG's (NYSE: NVS) Generic arm Sandoz on proposed versions of its bone-strengthening drugs Prolia and Xgeva containing denosumab, infringing several... 
Via Benzinga
AMGN LOSS ALERT: ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action - AMGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
2 Incredibly Cheap Dividend Stocks to Buy in May
These two dividend-paying pharma stocks both screen as significantly undervalued right now. 
Via The Motley Fool
Market Briefing For Tuesday, May 2 '23
Future earnings power is not as weak as 'bears' contend' but that also might mean the Fed's mistaken view they can temper inflation with another hike could provoke both a market sell-off and ensuing... 
Via Talk Markets
Why Amgen Shares Are Trading Lower Today
Amgen Inc (NASDAQ: AMGN) reported Q1 FY23 sales of $6.11 b 
Via Benzinga
Check Out What Whales Are Doing With AMGN
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $600 Today
Via Benzinga
A Look Into Amgen's Debt
Via Benzinga
Analyst Sees A Multibagger, Initiates Coverage On This 'Top Notch Biosimilar Business'
Truist initiated coverage on Coherus BioSciences Inc (NASDAQ: CHRS) with a Buy rating and a  
Via Benzinga
AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amgen Inc. (NASDAQ: AMGN)
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DraftKings, SVB, and Amgen and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Price Over Earnings Overview: Amgen
Via Benzinga
Where Amgen Stands With Analysts
Via Benzinga
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action - AMGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
Eli Lilly's Diabetes Newcomer, Mounjaro, Just Blew Sales Projections Out Of The Water
Mounjaro topped first-quarter sales expectations by more than $100 million. 
Via Investor's Business Daily
US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet'
Tech earnings could come to the market’s rescue on Thursday, with all major index futures currently trading higher. 
Via Benzinga
Amgen Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Amgen Inc. of Deadline in Securities Fraud Class Action Lawsuit
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, and Signature and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Thinking Of Buying Healthpeak Properties? Here Are The Properties And Tenants You'd Be Adding To Your Portfolio
Real estate investment trusts (REITs) are one of the most popular income-oriented types of stocks investors can purchase. Receiving monthly or quarterly dividend payments on a regular basis is... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
As Its Stock Gets Set For Upgrade, Boan Biotech Still Faces Two Big Risks
Key Takeaways: With two products now generating revenue, Boan Biotech will soon have the “B” marker for high-risk tickers removed from its stock symbol Boan faces stiff competition in its main area of... 
Via Benzinga
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Match, DraftKings, SVB, and Amgen and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amgen Inc. (NASDAQ: AMGN)
From Bernstein Liebhard LLP
Via GlobeNewswire
7 Dividend Stocks to Buy That Are Backed by Strong Cash Flows
Cash is king and this article highlights seven dividend stocks with strong cash flows and an emphasis on free cash flow. 
Via InvestorPlace
Novo Nordisk Surges To Another Record As Obesity Drugs Drive Higher Outlook
Demand for Wegovy and Ozempic prompted Novo to raise its full-year outlook. 
Via Investor's Business Daily
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DraftKings, SVB, Amgen, and Signature and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.